GlassScriptPhysician profile
Nathan M Schomaker
NPI 1225472327
$343,647.60
in general payments reported to CMS, 2019-2025
16 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.26 · 2020: $42.17 · 2021: $25.87 · 2022: $26K · 2023: $142K · 2024: $44K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $316K · Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $315,598.33 |
| Food and Beverage | $1,525.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $341,525.54 | 2022-2025 | Capsocam Plus, Capsocam Colon |
| Abbvie INC. | $1,196.88 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Celgene Corporation | $174.68 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $123.07 | 2024 | Omvoh |
| Gilead Sciences, INC. | $101.11 | 2023-2024 | |
| Janssen Biotech, INC. | $86.03 | 2019-2023 | Remicade, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $76.70 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $61.75 | 2023 | Idacio |
| Genzyme Corporation | $53.41 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $52.23 | 2023 | Dupixent |
| Pfizer INC. | $50.86 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.54 | 2019-2020 | |
| Ardelyx, INC. | $28.78 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $28.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.37 | 2023 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $18.44 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Schomaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.